Shots: The US FDA’s approval is based on two P-III studies, LEAP 1 & LEAP 2. LEAP 1 involves assessing of Xenleta (150mg IV/600mg oral for 5-7days) vs moxifloxacin (IV/oral […]readmore
Tags : Community-Acquired Bacterial Pneumonia
Regulatory
Paratek Pharmaceuticals’ Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial
Shots: The approval is based on multiple trial study assessing Nuzyra and resulted in safe, efficacious and well tolerated results Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial […]readmore